Minimizing intestinal dysfunction

• US 9,962,432 B2
• Filed: 02/16/2016
• Issued: 05/08/2018
• Est. Priority Date: 10/02/2010
• Status: Active Grant

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: DeLano, Frank A., Schmid-Schoenbein, Geert W., Saltzman, Darin
• Primary Examiner(s): Garyu, Lianko G
• Application Number:
  US15/044,356
• Publication Number:
  US 20160367642A1
• Time in Patent Office: 812 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 31/415 1,2-Diazoles
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 31/497 containing further heterocyclic rings
• CPC Class Codes: A61K 38/38 Albumins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents

Abstract

Techniques are disclosed for treating or reducing symptoms associated with abdominal dysfunction or ileus following surgery or other abdominal episode by treating the area with a combination of one or more protease, antibacterial compound, and inflammatory lipid mediator.

Claims

1. A method for treating ileus, the method comprising:

administering to an individual a therapeutic dose of;

an inhibitor of a degrading enzyme, wherein the inhibitor of a degrading enzyme is cyclokapron at a dose of 10 to 50 mg/100 ml;

an antibacterial compound; and

an inflammatory lipid mediator binding protein.

2. The method of claim 1, wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.

3. The method of claim 2, wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

4. The method of claim 1, wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins.

5. The method of claim 4, wherein the dose of inflammatory lipid mediator binding protein is 10 to 50 mg/100 ml.

6. The method of claim 1, wherein the administering step is prophylactically into the abdominal cavity.

7. A method for treating abdominal dysfunction, the method comprising:

administering to an individual a therapeutic dose of;

an inhibitor of a degrading enzyme, wherein the degrading enzyme is cyclokapron with a dose of 10 to 50 mg/100 ml;

an antibacterial compound; and

an inflammatory lipid mediator binding protein.

8. The method of claim 7, wherein the antibacterial compound is effective against gram-positive and gram-negative bacteria.

9. The method of claim 8, wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

10. The method of claim 7, wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins.

11. The method of claim 10, wherein the dose of inflammatory lipid mediator binding protein is 10 to 50 mg/100 ml.

12. The method of claim 7, wherein the administering step is prophylactically into the abdominal cavity.

13. A method for treating ileus, the method comprising:

administering to an individual a therapeutic dose of;

an inhibitor of a degrading enzyme, wherein the degrading enzyme is a serine protease, a plasma protease, an MMP, an amylase or a lipase;

an antibacterial compound; and

an inflammatory lipid mediator binding protein, wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins at a dose of 10 to 50 mg/100 ml.

14. The method of claim 13, wherein the inhibitor of a degrading enzyme is cyclokapron.

15. The method of claim 13, wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

16. The method of claim 13, wherein the administering step is prophylactically into the abdominal cavity.

17. A method for treating abdominal dysfunction, the method comprising:

administering to an individual a therapeutic dose of;

an inhibitor of a degrading enzyme, wherein the degrading enzyme is a serine protease, a plasma protease, an MMP, an amylase or a lipase;

an antibacterial compound; and

an inflammatory lipid mediator binding protein, wherein the inflammatory lipid mediator binding protein is selected from the group consisting of albumin and free fatty acid binding proteins at a dose of 10 to 50 mg/100 ml.

18. The method of claim 17, wherein the inhibitor of a degrading enzyme is cyclokapron.

19. The method of claim 17, wherein the antibacterial compound includes one or more of ciprofloxacin, metronidazole, imipenem, cilastatin, ticarcillin, clavulanate, cefuroxime, and doxycycline.

20. The method of claim 17, wherein the administering step is prophylactically into the abdominal cavity.